The global sustained release excipients market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The increasing prevalence of chronic and topical diseases across the globe has created demand for sustained release excipients which in turn is driving the global sustained release excipients market. In addition, the acquired benefits of continuous or controlled drug release among patients is also exacerbated for the sustained release excipients market demand.
(Get 15% Discount on Buying this Report)
A full report of Global Sustained Release Excipients Market is available at: https://orionmarketreports.com/sustained-release-excipients-market/93100/
In June 2020, Evonik launched the RESOMER Precise platform of custom functional excipients to precisely manage the release profile of the parent drug products. Such developments are expected to help the sustained release excipients market growth during the forecast period.
In addition, sustained-release excipients market providers provide their services through retail channels and it increased opportunities for collaborative research in child development those are driven by the emergence of new laws, increased funding opportunities, and increased relationships between private and public companies.The prevalence of the development of excipients substances used in all types of aids such as solid oral ingredients and the formation of liquid, flexible, dispersed, and multi-functional substances.
Furthermore, continued investment in R&D, the presence of advanced research institutes, and the presence of leading pharmaceutical and biopharmaceutical companies create various new opportunities that will contribute to the growth of the sustained release excipients market. For instance, in January 2019, Croda International acquired the Brenntag Biosector for its vaccine with adjuvants portfolio that would be complementary to Croda’s medical excipients portfolio.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- GlaxoSmithKline plc, Mylan N.V.,Novartis AG Pfizer, Inc., Sun Pharmaceutical Inc. Ltd., and Salix Pharmaceuticals, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Sustained-release excipients Market Report by Segment
By Type
- Inorganic Chemicals
- Organic Chemicals
By Application
- Oral
- Parenteral
- Topical
By Distribution Channel
- Online Pharmacy
- Retail Pharmacy
- Others
- Middle East & Africa
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
